BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, Rieber N, Hufnagel M, Jansson AF, Hedrich C, Winowski H, Berger T, Foeldvari I, Ganser G, Hospach A, Huppertz HI, Mönkemöller K, Neudorf U, Weißbarth-Riedel E, Wittkowski H, Horneff G, Foell D; PRO-KIND SJIA project collaborators. Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany. Pediatr Rheumatol Online J 2018;16:7. [PMID: 29357887 DOI: 10.1186/s12969-018-0224-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Chuamanochan M, Weller K, Feist E, Kallinich T, Maurer M, Kümmerle-Deschner J, Krause K. State of care for patients with systemic autoinflammatory diseases - Results of a tertiary care survey. World Allergy Organ J 2019;12:100019. [PMID: 30937142 DOI: 10.1016/j.waojou.2019.100019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
2 Hinze C, Fuehner S, Kessel C, Wittkowski H, Lainka E, Baehr M, Hügle B, Haas J, Ganser G, Weißbarth‐riedel E, Jansson A, Foell D. Impact of IL1RN Variants on Response to Interleukin‐1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol 2020;72:499-505. [DOI: 10.1002/art.41130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Lainka E, Baehr M, Raszka B, Haas JP, Hügle B, Fischer N, Foell D, Hinze C, Weissbarth-Riedel E, Kallinich T, Horneff G, Windschall D, Lilienthal E, Niehues T, Neudorf U, Berendes R, Küster RM, Oommen PT, Rietschel C, Lutz T, Weller-Heinemann F, Tenbrock K, Heubner GL, Klotsche J, Wittkowski H. Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry. Pediatr Rheumatol Online J 2021;19:38. [PMID: 33752669 DOI: 10.1186/s12969-021-00510-8] [Reference Citation Analysis]
4 Batu ED. Glucocorticoid treatment in juvenile idiopathic arthritis. Rheumatol Int 2019;39:13-27. [PMID: 30276425 DOI: 10.1007/s00296-018-4168-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
5 Vollbach K, Schuetz C, Hedrich CM, Speth F, Mönkemöller K, Brunner J, Neudorf U, Rietschel C, Hospach A, Kallinich T, Hinze C, Wagner N, Tönshoff B, Weber LT, Latta K, Thumfart J, Bald M, Wiemann D, Zappel H, Tenbrock K, Haffner D. Working Towards a Treat-to-Target Protocol in Juvenile Proliferative Lupus Nephritis – A Survey of Pediatric Rheumatologists and Nephrologists in Germany and Austria. Front Pediatr 2022;10:851998. [DOI: 10.3389/fped.2022.851998] [Reference Citation Analysis]
6 He T, Xia Y, Yang J. Systemic inflammation and chronic kidney disease in a patient due to the RNASEH2B defect. Pediatr Rheumatol Online J 2021;19:9. [PMID: 33482855 DOI: 10.1186/s12969-021-00497-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Park C, Miranda-Garcia M, Berendes R, Horneff G, Kuemmerle-Deschner J, Ganser G, Huppertz HI, Minden K, Haas JP, Jansson AF, Borte M, Schuetz C, Oommen P, Frosch M, Schlueter B, Richter-Unruh A, Kessel C, Hinze C, Wittkowski H, Roth J, Foell D, Holzinger D. MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. Rheumatology (Oxford) 2021:keab729. [PMID: 34559193 DOI: 10.1093/rheumatology/keab729] [Reference Citation Analysis]
8 Föll D, Wittkowski H, Hinze C. [Still's disease as biphasic disorder : Current knowledge on pathogenesis and novel treatment approaches]. Z Rheumatol 2020;79:639-48. [PMID: 32253510 DOI: 10.1007/s00393-020-00779-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Hinze CH, Oommen PT, Dressler F, Urban A, Weller-Heinemann F, Speth F, Lainka E, Brunner J, Fesq H, Foell D, Müller-Felber W, Neudorf U, Rietschel C, Schwarz T, Schara U, Haas JP. Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. Pediatr Rheumatol Online J 2018;16:40. [PMID: 29940960 DOI: 10.1186/s12969-018-0257-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
10 Tomaras S, Goetzke CC, Kallinich T, Feist E. Adult-Onset Still's Disease: Clinical Aspects and Therapeutic Approach. J Clin Med 2021;10:733. [PMID: 33673234 DOI: 10.3390/jcm10040733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Onel K, Rumsey DG, Shenoi S. Juvenile Idiopathic Arthritis Treatment Updates. Rheum Dis Clin North Am 2021;47:545-63. [PMID: 34635291 DOI: 10.1016/j.rdc.2021.07.009] [Reference Citation Analysis]
12 Hinze T, Kessel C, Hinze CH, Seibert J, Gram H, Foell D. A dysregulated interleukin-18-interferon-γ-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 2021;60:5165-74. [PMID: 33576397 DOI: 10.1093/rheumatology/keab113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
13 Horneff G. [New drugs for treatment of juvenile idiopathic arthritis]. Z Rheumatol 2019;78:587-98. [PMID: 31098699 DOI: 10.1007/s00393-019-0646-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
14 Hansmann S, Lainka E, Horneff G, Holzinger D, Rieber N, Jansson AF, Rösen-Wolff A, Erbis G, Prelog M, Brunner J, Benseler SM, Kuemmerle-Deschner JB. Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative. Pediatr Rheumatol Online J 2020;18:17. [PMID: 32066461 DOI: 10.1186/s12969-020-0409-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
15 Vollbach K, Eulert S, Horneff G, Föll D, Tenbrock K, Minden K. Pro-Kind Rheuma – aktueller Stand des GBA-Projektes. Aktuelle Rheumatologie 2022;47:110-6. [DOI: 10.1055/a-1769-4355] [Reference Citation Analysis]
16 Kiuchi Z, Ogura M, Sato M, Kamei K, Ishikura K, Abe J, Ito S. No preventive or therapeutic efficacy of infliximab against macrophage activation syndrome due to systemic juvenile idiopathic arthritis. Scand J Rheumatol 2019;48:246-8. [PMID: 30406708 DOI: 10.1080/03009742.2018.1493745] [Reference Citation Analysis]
17 Lehmann R, Ries M. Spectrum of Clinical Research in Juvenile Idiopathic Arthritis: A Cross-Sectional Analysis of Registered Studies in Clinicaltrials.gov and Clinicaltrialsregister.eu. Biomedicines 2021;9:1860. [PMID: 34944676 DOI: 10.3390/biomedicines9121860] [Reference Citation Analysis]
18 Vastert SJ, Jamilloux Y, Quartier P, Ohlman S, Osterling Koskinen L, Kullenberg T, Franck-Larsson K, Fautrel B, de Benedetti F. Anakinra in children and adults with Still's disease. Rheumatology (Oxford) 2019;58:vi9-vi22. [PMID: 31769856 DOI: 10.1093/rheumatology/kez350] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 13.0] [Reference Citation Analysis]
19 Gohar F, Mcardle A, Jones M, Callan N, Hernandez B, Kessel C, Miranda-garcia M, Lavric M, Holzinger D, Pretzer C, Lainka E, Vastert SJ, de Roock S, Fitzgerald O, Pennington SR, Foell D. Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis. Ann Rheum Dis 2019;78:1107-13. [DOI: 10.1136/annrheumdis-2019-215051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
20 Ter Haar NM, van Dijkhuizen EHP, Swart JF, van Royen-Kerkhof A, El Idrissi A, Leek AP, de Jager W, de Groot MCH, Haitjema S, Holzinger D, Foell D, van Loosdregt J, Wulffraat NM, de Roock S, Vastert SJ. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study. Arthritis Rheumatol 2019;71:1163-73. [PMID: 30848528 DOI: 10.1002/art.40865] [Cited by in Crossref: 57] [Cited by in F6Publishing: 43] [Article Influence: 19.0] [Reference Citation Analysis]
21 Kudela H, Drynda S, Lux A, Horneff G, Kekow J. Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still's disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. BMC Rheumatol 2019;3:4. [PMID: 30886992 DOI: 10.1186/s41927-019-0053-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
22 Keenan P, Brunner J, Quan AS, Smitka M, Hahn G, Pain CE, Häfner R, Speth F, Gerstl L, Hedrich CM. Diagnosis and Treatment of Small Vessel Childhood Primary Angiitis of the Central Nervous System (sv-cPACNS): An International Survey. Front Pediatr 2021;9:756612. [PMID: 34712632 DOI: 10.3389/fped.2021.756612] [Reference Citation Analysis]
23 Çakan M, Karadağ ŞG, Tanatar A, Ayaz NA. The frequency of macrophage activation syndrome and disease course in systemic juvenile idiopathic arthritis. Mod Rheumatol 2020;30:900-4. [PMID: 31462146 DOI: 10.1080/14397595.2019.1660026] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
24 Kearsley-Fleet L, Heaf E, Davies R, Baildam E, Beresford MW, Foster HE, Southwood TR, Thomson W, Hyrich KL; BCRD and BSPAR-ETN study groups. Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study. Lancet Rheumatol 2020;2:e217-26. [PMID: 32280951 DOI: 10.1016/S2665-9913(20)30025-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
25 Horneff G. 5/w mit Gelenkschmerzen: Vorbereitung auf die Facharztprüfung: Fall 41. Monatsschr Kinderheilkd. [DOI: 10.1007/s00112-021-01389-1] [Reference Citation Analysis]
26 Alkwai HM, Mirza A, Abdwani R, Asiri A, Bakry R, Alenazi A, Khawaja K, Lotfy H, Almutairi M, Muzaffer M, Al-Suwairi W, Alzyoud R, Al-Mayouf SM. Consensus clinical approach for a newly diagnosed systemic juvenile idiopathic arthritis among members of the pediatric rheumatology Arab group. Int J Pediatr Adolesc Med 2021;8:129-33. [PMID: 34350323 DOI: 10.1016/j.ijpam.2021.05.003] [Reference Citation Analysis]
27 Haas JP, Arbogast M. [Therapeutic options in juvenile idiopathic arthritis : Part 1: Nonsurgical treatment]. Orthopade 2018;47:912-8. [PMID: 30291372 DOI: 10.1007/s00132-018-3645-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Henderson LA. A Bullseye for Children With Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol 2019;71:1030-3. [PMID: 30802004 DOI: 10.1002/art.40867] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Mejbri M, Theodoropoulou K, Hofer M, Cimaz R. Interleukin-1 Blockade in Systemic Juvenile Idiopathic Arthritis. Pediatr Drugs 2020;22:251-62. [DOI: 10.1007/s40272-020-00392-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
30 Quan AS, Brunner J, Rose B, Smitka M, Hahn G, Pain CE, Häfner R, Speth F, Gerstl L, Hedrich CM. Diagnosis and Treatment of Angiography Positive Medium to Large Vessel Childhood Primary Angiitis of Central Nervous System (p-cPACNS): An International Survey. Front Pediatr 2021;9:654537. [PMID: 33842414 DOI: 10.3389/fped.2021.654537] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Sur LM, Gaga R, Duca E, Sur G, Lupan I, Sur D, Samasca G, Lazea C, Lazar C. Different Chronic Disorders That Fall within the Term Juvenile Idiopathic Arthritis. Life (Basel) 2021;11:398. [PMID: 33925491 DOI: 10.3390/life11050398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Yan X, Tang W, Zhang Z, Zhang Y, Luo C, Tang X. Tocilizumab in Systemic Juvenile Idiopathic Arthritis: Response Differs by Disease Duration at Medication Initiation and by Phenotype of Disease. Front Pediatr 2021;9:735846. [PMID: 34820342 DOI: 10.3389/fped.2021.735846] [Reference Citation Analysis]
33 Haas J, Minden K. Langfristentwicklungen in der Kinder- und Jugendrheumatologie. Aktuelle Rheumatologie. [DOI: 10.1055/a-1526-9370] [Reference Citation Analysis]
34 El Miedany Y, Salah S, Lotfy H, El Gaafary M, Abdulhady H, Salah H, Nasef SI, El-latif EA, Farag Y, Eissa M, Esam Maher S, Radwan A, El-shanawany AT, Medhat BM, El Mikkawy D, Mosa DM, El Deriny G, Mortada M, Osman NS, Fouad NA, Elkaraly NE, Mohamed SS, Tabra SA, Hassan WA, Amer Y, Abu-zaid MH. Updated clinical practice treat-to-target guidelines for JIA management: the Egyptian College of Pediatric Rheumatology initiative. Egypt Rheumatol Rehabil 2022;49. [DOI: 10.1186/s43166-022-00125-1] [Reference Citation Analysis]
35 Bielak M, Husmann E, Weyandt N, Haas JP, Hügle B, Horneff G, Neudorf U, Lutz T, Lilienthal E, Kallinich T, Tenbrock K, Berendes R, Niehues T, Wittkowski H, Weißbarth-Riedel E, Heubner G, Oommen P, Klotsche J, Foell D, Lainka E. IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry). Pediatr Rheumatol Online J 2018;16:22. [PMID: 29622022 DOI: 10.1186/s12969-018-0236-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
36 Arbogast M, Haas JP. [Injuries in children and adolescents with inflammatory rheumatic diseases : Special risks and techniques for fracture treatment of the growing skeleton]. Unfallchirurg 2020;123:607-15. [PMID: 32444884 DOI: 10.1007/s00113-020-00818-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]